Circle Pharma has initiated a clinical trial to evaluate
the safety and efficacy of CID-078, as monotherapy
across a range of solid tumors.
This first-in-human, Phase 1, multi-center, open-label, dose-escalation, dose-expansion study is evaluating CID-078 in patients with advanced cancer. This study is being conducted in two parts. The primary purpose of Part 1 is to evaluate safety and identify one or more doses for expansion (Part 2). Part 2 will evaluate anti-tumor efficacy and further characterize the safety, tolerability, and pharmacokinetics of the CID-078 dose(s) selected in Part 1.
Visit ClinicalTrials.gov (NCT06577987) for more information about this trial.
CID-078 is an investigational agent whose safety and efficacy in solid tumor malignancies has not been evaluated by the FDA or any other regulatory Agency.
This site is intended for US residents only.
© 2024 Circle Pharma. All Rights Reserved.
Subscribe to our News Alerts
